Insulin Therapy Center

With pressure from patients, elected representatives and the medical community, we are finally seeing some positive results in lowering the cost of a life-sustaining drug.

Two long-acting insulin analogs are compared for efficacy and side effects.

A study tests postprandial inhaled glucose for a more natural insulin effect.

SGLT shown as useful adjunctive agent when insulin monotherapy fails, but decrease in insulin use may prove harmful.

Study investigates preservation or improvement of B-cell function using metformin with or without short-term insulin.

In this week's Homerun Slides, insulin initiation and a comparison of pharmacokinetic and pharmacodynamic insulins.

ADA 2018 abstracts of interest include Entresto for the Treatment of Diabetic Peripheral Neuropathy; Oral Contraceptive Associated with Postmenopausal Diabetes; Glucokinase as Adjunct Therapy in People with Type 1 Diabetes, and more.

We all know the benefits of the newer insulins, i.e., faster action times, less peak from the long actings, etc. But the cost, more often than we know, can lead to patients decreasing insulin doses, doing without until the next payday, or doing without it altogether, as we’ve read about. …

Guest Post by David Kliff, Editor, Diabetic Investor

The so-called “high” cost of insulin continues to get lots of attention. But as I’ve noted before, little perspective has been given to this debate and far too many facts are missing. Yes, I know facts are pesky things, but they are facts nonetheless. Allow me for a moment to provide some examples.

Evaluating if bolus calculators for insulin pumps can be accurately calibrated by speech recognition.